3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Prostate Cancer
1
Mouth Neoplasms
1
Melanoma
1
Lung Diseases
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
5
copper dotatate CU-64
3
Magnetic Resonance Spectroscopy
3
lanreotide
2
gallium Ga 68 dotatate
2
Nivolumab
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Carboplatin
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
pasireotide
1
irinotecan sucrosofate
1
folfirinox
1
cabozantinib
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Somatostatin
1
Resveratrol
1
Radiosurgery
1
Octreotide
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled